Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.

DR, Hargrave; E, Bouffet; U, Tabori; A, Broniscer; KJ, Cohen; JR, Hansford; B, Geoerger; P, Hingorani; IJ, Dunkel; MW, Russo; L, Tseng; K, Dasgupta; E, Gasal; JA, Whitlock; MW, Kieran

doi:10.1158/1078-0432.ccr-19-2177

Public

Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.

Shared by NobleBlocks on Dec 1, 2019 • 12:00 AM UTC

Authors:

Hargrave DR

Bouffet E

Tabori U

Abstract

Purpose Pediatric low-grade glioma (pLGG) is the most prevalent childhood brain tumor. Patients with BRAF V600 mutation-positive pLGG may benefit from treatment with dabrafenib. Part 2 of a phase I/IIa study, open-label study (NCT01677741) explores the activity and safety of dabrafenib treatment in ...

Discussions